Levetiracetam

MONDAY, Dec. 2, 2024 -- For decades, it's been known that certain older medications women use to control epilepsy seizures can pose risks to a fetus. However, data now suggests that no such risk exists for newer-generation anti-seizure meds. “We need to balance making sure there is enough medicine on board to protect the mother and her developing fetus from seizures, but not too much where we're creating risk for the child,” explained study co-lead investigator Dr. Kimford Meador , a professor of neurology at Stanford University. Older medications such as valproate have been strongly linked to birth defects and cognitive issues in offspring. So, women with epilepsy have long been warned to stay off of these drugs while pregnant. However, seizure control is important, since seizures can also pose risks to the fetus and mother-to-be. New anti-seizure medications have been developed -- but do they pose any risk to the fetus? To find out, Meador's team tracked the language development of 387 children. Kids were tracked up to the age of 6. Of those, 298 had been born to women with epilepsy who took newer antiseizure medications while pregnant -- typically lamotrigine , levetiracetam or a combination of both drugs. "Children were tested on a variety of verbal abilities, including vocabulary and matching spoken words to pictures," according to a news release from the National Institute of Neurological Disorders and Stroke (NINDS), which funded the study. The result: No difference in language scores between kids exposed to the drugs in the womb and those who were not exposed. “What makes this study meaningful is that when you assess a child at 6, the tests are a lot more sensitive than at earlier ages, especially 2-year-olds," Meador noted in the news release. "There’s measurable impact on school performance and results are more predictive of adult cognitive ability." The new findings should reassure parents, since prior studies that had followed kids only up to age 2 or 3 had suggested that fetal exposure to high doses of levetiracetam might impair a child's cognitive skills. However, by 6 years of age, no differences were found, according to the new research. “Controlling seizures during pregnancy is an important part of prenatal care for women with epilepsy, but for years, the effects of newer antiseizure medications on their children was unknown,” noted Dr. Adam Hartman , program director at NINDS. “One major component of this study was correlating the cognitive abilities of children with maternal blood levels of the drugs. This opens the door to future work and might inform better dosing strategies," said Hartman, who wasn't involved in the study. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

The new company aims to deliver quality treatments and address evolving neurology treatment needs in the country. Credit: Volha_R/Shutterstock. CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge’s ( UCB ) mature neurology and allergy business in China for $680m. The move comes after UCB agreed to sell and license its business in August 2024. The deal encompasses UCB’s Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro. They are set to be the cornerstone assets for CBC as it develops an integrated central nervous system (CNS) biopharma platform in China. Working alongside Mubadala, CBC plans to leverage its platform synergies, investor-operator approach and healthcare expertise, to optimise operations, foster innovation and expand its reach to benefit more patients in the region. The new entity formed from this acquisition called NeuroGen Pharma is set to offer neuro healthcare innovation services. It will be spearheaded by a management team with a solid background in the biopharma industry, which is expected to ensure a seamless transition and drive future growth. The company aims to deliver quality treatments and address the evolving neurology treatment needs in the country. The acquired portfolio reported combined net sales of €131m ($138m) in 2023. The strategic acquisition is part of a broader partnership between CBC and Mubadala, which also includes their joint investment in the $315m fundraising round for Hasten and an investment in CBC Healthcare Infrastructure Platform’s first life science real assets venture. CBC Group CEO Fu Wei stated: “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. “This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market.”